Cód QR

Gender impact on safety and efficacy in lenvatinib treated patients with radioiodine-refractory differentiated thyroid cancer (GISEL study)

Introduction: Little is known about sex differences in lenvatinib treatment safety and efficacy. Methods: Real-word retrospective Italian multicenter study enrolling patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Results: A total of 138 patients (64 femal...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Giulia Puliani, Marta Bianchini, Carlotta Giani, Laura Valerio, Alice Nervo, Giulia Sapuppo, Giorgio Grani, Cristina Dalmiglio, Simone De Leo, Rosa Lauretta, Marilda Mormando, Irene Terrenato, Stefania Zovato, Laura Fugazzola, Maria Grazia Castagna, Cosimo Durante, Gabriella Pellegriti, Emanuela Arvat, Rossella Elisei, Marialuisa Appetecchia
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: Bioscientifica 2025-04-01
Sraith:European Thyroid Journal
Ábhair:
lenvatinib
sex
gender
efficacy
safety
radioiodine-refractory differentiated thyroid cancer
Rochtain ar líne:https://etj.bioscientifica.com/view/journals/etj/14/2/ETJ-24-0386.xml
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla